ELV — Elevance Health Inc.

Elevance Health (ELV) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Diluted EPS: Reported at $7.45, exceeding expectations.
• Full-Year 2026 EPS Guidance: Raised to at least $27, with a baseline for modeling purposes set at $26.
• Operating Revenue: Totaled $49.8 billion, a 0.8% year-over-year increase, driven by higher premium yields and product revenue.
• Medical Members: Ended the quarter with 44.9 million members, reflecting a known fee-based customer transition and attrition in individual ACA and Medicaid segments.
• Operating Cash Flow: Increased to at least $6 billion for the year, benefiting from strong performance and timing of Medicaid payments.

2. Strategic Updates and Business Highlights

• Medicare Advantage: Improved performance attributed to disciplined plan design and favorable claims experience, with expectations for at least a 2% operating margin in 2026.
• Medicaid: Managed with discipline; second quarter performance supports a full-year margin outlook of approximately -1.75%. Actions taken to improve performance are maturing.
• Individual ACA Business: Performance aligns with expectations; higher mix of bronze plans leads to more pronounced seasonality.
• Commercial Business: Strong demand for integrated medical and pharmacy models, with a focus on affordability and member experience.
• Carelon: Continued expansion of value-based solutions, particularly in behavioral health and home care, contributing to long-term growth.

3. Forward Guidance and Outlook

• 2027 Outlook: Confidence in returning to at least 12% adjusted EPS growth, supported by diversified earnings contributions across all business lines.
• Medicaid: Expected to improve margins as rates align with costs and care management actions mature.
• Medicare Advantage and ACA: Bids for 2027 reflect a disciplined approach to cost trends and sustainable margins.

4. Bad News, Challenges, or Points of Concern

• Medicaid Environment: Remains dynamic with elevated cost pressures in behavioral health, specialty pharmacy, and emergency services. Exiting underperforming markets is a focus, with potential additional exits anticipated.
• Utilization Trends: Elevated utilization among remaining members, with no significant reset in acuity expected but ongoing pressure from known cost drivers.
• Regulatory Changes: Potential impacts from upcoming regulations (e.g., OBBBA) and work requirements could affect Medicaid funding and member dynamics.

5. Notable Q&A Insights

• Medicaid Exits: Management confirmed plans to exit additional Medicaid markets where sustainable performance is not achievable, emphasizing a disciplined approach to market participation.
• Utilization Trends: Clarified that while outpatient surgery trends are not universally high, they are a significant cost driver in certain segments, particularly Medicaid.
• Investments: One-time investments funded by non-recurring benefits will not recur in 2027, aimed at enhancing operational capabilities and cost management.
• Market Dynamics: Strong demand for integrated offerings in the commercial sector, with a notable return of clients who previously left Elevance.

Overall, Elevance Health's Q2 2026 results reflect strong operational execution and strategic investments, although challenges in the Medicaid sector and regulatory uncertainties remain points of concern.